Fierce BioTech

JULY 1, 2024

Streamlining the Path from Discovery to Patient – Simpler RNA Manufacturing with Aldevron’s Codex® HiCap RNA Polymerase swheeler Mon, 07/01/2024 - 17:17 Wed, 08/07/2024 - 10:00 Resource Type Webinar Kyle Studey, M.S. Codex ® is a trademark of Codexis, Inc. Listing Image aldevron 250x190.png

RNA 40

RNA Engineering Research 40

Drug Target Review

APRIL 7, 2025

Haemoglobin A1c (HbA1c) is a validated surrogate endpoint for the reduction of microvascular complications associated with diabetes mellitus; reduced HIV-RNA levels serve as an endpoint for HIV disease control; and a reduction in low-density lipoprotein (LDL) cholesterol is used as an endpoint indicating lower likelihood of cardiovascular events.

Clinical Development 59

Clinical Development Clinical Trials Clinical Pharmacology Trials 59

Drug Target Review

JULY 5, 2023

At PEGS Europe, Drug Target Review spoke to Victoria Goldenshtein, a PhD candidate in Biomedical Engineering at Duke University, US, who presented an engaging poster on her lab’s novel in vitro library display platform for directed protein evolution termed GRIP Display, which entails Gluing RNA to Its Proteins.

RNA 97

RNA Engineering Disease Drugs 97

Chemical Biology and Drug Design

DECEMBER 28, 2023

The prognostic value of long noncoding RNA (lncRNA) LINC00460 has been reported in cervical cancer. In present study, LINC00460 was screened out through bioinformatics analysis. Abstract The acquired resistance of cancer to cisplatin (DDP) limits the efficacy of chemotherapy.

Bioinformatics 100

Bioinformatics RNA Regulations Drugs 100

The Pharma Data

JUNE 14, 2023

Scientists discover small RNA that regulates bacterial infection People with weakened immune systems are at constant risk of infection. Using genetic sequencing technologies, Whiteley and Cao measured the levels of all types of mRNA present in the bacteria. They named the small RNA SicX (sRNA inducer of chronic infection X).

RNA 40

RNA Regulations Treatment Research 40

Chemical Biology and Drug Design

DECEMBER 1, 2023

At present, it has not been reported whether BD inhibits the malignancy of colorectal cancer (CRC) cells. circinteractome, and CircBank and validated using dual-luciferase reporter and RNA pull-down assays. BD could restrain CRC growth through repressing the circ_0068464/miR-520h/ATG5 axis.

RNA 100

RNA Regulations Treatment Drugs 100

Chemical Biology and Drug Design

SEPTEMBER 15, 2023

CRS rabbit models were constructed by Staphylococcus aureus infection and rabbits were injected with lentiviral vectors of short hairpin RNA-targeting Chemerin (shChemerin), followed by micro-computed tomography (CT) scan. Patients suffering from CRS without/with nasal polyps (CRSsNP/CRSwNP), along with volunteers, were recruited.

RNA 100

RNA Treatment Disease Research 100

DrugBank

MAY 22, 2024

In the dynamic world of drug discovery, the notion of "undruggable" targets presents both a significant challenge and an intriguing frontier for researchers and pharmaceutical companies. Beyond Proteins: DNA and RNA Frontier The story doesn’t end with proteins.

Small Molecule 96

Small Molecule RNA DNA Pharmaceutical Companies 96

The Pharma Data

SEPTEMBER 6, 2021

First data to be presented from the phase II coopERA Breast Cancer study evaluating neoadjuvant giredestrant treatment for oestrogen receptor (ER)-positive, HER2-negative breast cancer. Breast Cancer Highlights. Lung Cancer Highlights.

Treatment 52

Treatment Therapies DNA Trials 52

ASPET

MARCH 26, 2024

The messenger RNA for human H 1 -histamine-receptors was present in cardiac samples from H 1 -TG and absent from WT. In H 1 -TG mice, we ascertained the presence of H 1 -histamine receptors by autoradiography of atrium and ventricle using [ 3 H]mepyramine.

RNA 100

RNA 100

The Pharma Data

JULY 12, 2021

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of data from the company’s HIV clinical development program at the 11th International AIDS Society Conference on HIV Science (IAS 2021) from July 18-21. Late Breaking Oral Presentation OALC01LB03. On-Demand Oral Presentation OAB0304.

Pharmacokinetics 52

Pharmacokinetics Clinical Trials Trials Treatment 52

The Strateos Blog: Drug Discovery

DECEMBER 13, 2021

Senior Director, R&D Strategy, will be delivering a presentation highlighting how Strateos' smart lab platform accelerated riboswitch engineering to develop novel biosensors. Learn how Strateos’ automated synthetic biology modules supported rapid, iterative screening of RNA sequences in modular pbuE expression system and E.

Engineering 52

Engineering Protein Expression Research Laboratories RNA 52

The Pharma Data

OCTOBER 28, 2021

ViiV Healthcare presents positive interim data showing Vocabria (cabotegravir) and Rekambys (rilpivirine) can be enforced successfully in a variety of European healthcare settings. 1), (2), (3) Interim findings were presented at the 18th European AIDS Conference (EACS 2021) being held 27-30 October. 5) HarmonyP.

Pharmaceutical Companies 52

Pharmaceutical Companies Treatment RNA Pharmaceuticals 52

The Pharma Data

MARCH 8, 2021

The data were presented at the 28th Conference on Retroviruses and Opportunistic Infections ( virtual CROI 2021). These data reinforce that Biktarvy provides durable viral suppression, strong efficacy and a high barrier to resistance in both adults that are new to HIV therapy and those replacing their existing treatment.”.

Treatment 52

Treatment Therapies RNA Laboratories 52

KIF1A

SEPTEMBER 16, 2023

Note: For simplicity I will use the term KIF1A when referring to UNC-104 Post-translational modifications: When we talk about modifications to proteins, it’s usually in the context of mutations – a modification to the KIF1A gene makes altered RNA, which translates into altered KIF1A protein.

Regulations 105

Regulations RNA Disease Research 105

Broad Institute

AUGUST 19, 2024

Using RNA sequencing and working with the Broad’s Metabolomics Platform and collaborators at St. Jude’s, the team identified a group of genes involved in processing uLCFAs that are present only in the non- Lactobacillus iners species.

Hospitals 121

Hospitals Treatment Medical Schools Science 121

DrugBank

MARCH 12, 2025

Introduction Messenger RNA (mRNA) technology has emerged as one of the most significant medical breakthroughs. Once delivered into the body, the mRNA instructs cells to produce these antigens, which are then presented to the immune system.

Vaccine 97

Vaccine Treatment Clinical Trials Therapies 97

Broad Institute

MARCH 6, 2024

In the new study, McCarroll, Berretta, and colleagues used single-nucleus RNA sequencing, which measures gene expression in individual cells, to better understand how the brain naturally varies across individuals. They analyzed 1.2 million cells from 94 people with schizophrenia and 97 without.

Medical Schools 134

Medical Schools RNA Science Research 134

The Pharma Data

MARCH 8, 2021

These preliminary findings were presented today during Science Spotlights TM at the 2021 Conference on Retroviruses and Opportunistic Infections (CROI 2021). Findings from the primary efficacy and safety endpoints and additional secondary objectives will be presented at an upcoming medical meeting. About Molnupiravir.

Trials 69

Trials Virus RNA Research Laboratories 69

KIF1A

SEPTEMBER 9, 2023

These cells are present in embryos, where they populate the brain by dividing: When a radial glial progenitor (RGP) divides it can make two radial glial progenitor copies to increase cell number, or it can make a single copy as well as a mature neuron.

RNA 105

RNA Treatment Research Disease 105

Drug Target Review

APRIL 9, 2024

Our approach to investigate the toxicity driven by nucleolar stress was to induce it with certain arginine-rich peptides, present in patients of ALS, which were known to accumulate at nucleoli and cause this type of stress. However, our study was first to show that inducing nucleolar stress in an adult mammal accelerates aging.

RNA 65

RNA Cell Biology Clinical Development DNA 65

Drug Target Review

JULY 5, 2023

In the study presented at ASGCT, what were the specific findings regarding the synergistic killing of SKOV3 ovarian tumour cells by the iPSC-derived lymphoid and myeloid cells? What are the key advancements in nucleic-acid delivery and targeted gene insertion that Eterna and Factor Bioscience presented at the ASGCT?

Therapies 104

Therapies DNA Engineering Virus 104

Broad Institute

OCTOBER 28, 2024

So we took lots of reference single-cell RNA sequencing data from atlases and used our scalable machine learning algorithms to embed all of the gene expression data on these cells into compact vector representations — you can think of these as a signature for each cell. We wanted to build a tool like that for cell biology.

Engineering 119

Engineering Cell Biology Disease RNA 119

The Pharma Data

MARCH 8, 2021

and Shionogi Limited as shareholders, today presented positive long-term data from its global phase IIIb ATLAS-2M study of the first complete, long-acting regimen of cabotegravir and rilpivirine for the treatment of HIV. Week 96 findings reinforce the primary (proportion of participants with plasma HIV-1 RNA ?50 4.3) [1].

RNA 52

RNA Treatment Therapies Licensing 52

Drug Target Review

NOVEMBER 13, 2023

The instructions to form a cell are encoded in DNA strands, wrapped in proteins and RNA, and wound together into a 3D structure called chromatin. When the researchers compared the architecture of regulatory and effector T cells, they found there were many unique Foxp3 binding regions only present in regulatory T cells.

Government 105

Government DNA RNA Regulations 105

Drug Target Review

SEPTEMBER 25, 2024

5 Here, the original oncogene is still present but the transdifferentiated cancer cells are less dependent on it. Investigating non-oncogene resistance as a parallel defense mechanism used by cancer cells to evade therapies could therefore present a significant opportunity to address drug resistance more comprehensively.

Small Molecule 105

Small Molecule Therapies Regulations Treatment 105

Fierce BioTech

JULY 26, 2023

Many targets have resisted conventional discovery approaches because they are highly conserved, structurally complex, or they present other technical hurdles. Duration 60 Minutes Despite the remarkable growth of antibody-based therapies in recent years, numerous promising targets remain untapped.

RNA 52

RNA Therapies Drugs 52

PerkinElmer

JANUARY 19, 2020

Here are ten key tutorials, presentations and posters designed to help you achieve fast, accurate and reproducible results in precision medicine, next generation sequencing, homogenous assays and more. Presenter: Thomas Rawlins, Automation Expert, PerkinElmer. Time away from the lab is limited and valuable.

International 52

International RNA DNA Science 52

PLOS: DNA Science

MARCH 28, 2024

A Scant Protein with Outsize Importance Slowing the muscle decline of DMD presents two huge challenges: the ubiquity of muscle and a giant gene. The gene presents a complex landscape. Results from the study that led to the FDA approval appeared in The Lancet Neurology in April 2024 with commentary.

FDA Approval 96

FDA Approval Treatment FDA DNA 96

The Pharma Data

JULY 12, 2021

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced today the presentation of previously announced Phase 2 interim results from two Phase 2/3 clinical trials (MOVe-OUT and MOVe-IN) of molnupiravir (MK-4482/EIDD-2801), an investigational oral antiviral therapeutic. About Molnupiravir.

Clinical Trials 52

Clinical Trials Laboratories Research Laboratories RNA 52

DrugBank

JULY 24, 2024

Additionally, while small molecules can target well-defined pockets on enzymes or receptors, targeting PPIs presents a unique challenge due to their flat, featureless interfaces and large interaction areas. Despite these challenges, the progress in PPI-modulating drugs is noteworthy.

Small Molecule 98

Small Molecule Drugs Clinical Trials Therapies 98

Broad Institute

SEPTEMBER 26, 2024

Researchers use single-cell RNA sequencing batch correction methods to remove batch effects from data, but these tools are originally not intended for images and may make incorrect assumptions. Here, we present a generalizable pipeline to benchmark batch correction methods on CellProfiler imaging-based morphological data.

RNA 52

RNA Science Disease Research 52

Drug Target Review

JUNE 6, 2023

In the context of a tumour microenvironment, Tregs are often present in high numbers, preventing an effective immune response to the tumour. 2 After activation by an antigen presenting cell, a T helper cell segregates the cytokines. Some approaches have already reached the clinical trial stage, with others not far behind.

Engineering 98

Engineering Immune Response Biochemical Pharmacology Clinical Trials 98

Broad Institute

JUNE 30, 2023

LipocyteProfiler is a powerful imaging technique that generates comprehensive microscopy-based profiles of cells using multiple fluorescent dyes chosen specifically for studies of cardiometabolic biology.

Small Molecule 105

Small Molecule Cell Based Assays Disease Assay Development 105

The Pharma Data

JULY 6, 2021

New research from first-in-class marketed and investigational therapies in hemophilia, immune thrombocytopenia and acquired thrombotic thrombocytopenic purpura will be presented. Oral presentation. Interim Phase 1/2 study data will be presented at ISTH. Oral Presentation. ePoster Abstract # OC48.2 Abstract # OC72.2

Therapies 52

Therapies Pharmacokinetics Treatment RNA 52

The Pharma Data

OCTOBER 14, 2020

Live Webcast : accessible from the Company’s website at www.eloxxpharma.com under Events and Presentations or with this link: [link]. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. About Eloxx Pharmaceuticals. Eloxx Pharmaceuticals, Inc. Eloxx Pharmaceuticals, Inc.

Pharmaceuticals 52

Pharmaceuticals RNA Small Molecule Protein Production 52

New Drug Approvals

SEPTEMBER 6, 2024

TLR7-9 are among the set that are endosomally located and respond to single-stranded RNA (TLR7and TLR8) or unmethylated single-stranded DNA containing cytosine-phosphate-guanine (CpG) motifs (TLR9). A total of 13 TLR family members have been identified, 10 in human, that span either the cell surface or the endosomal compartment.

RNA 62

RNA Clinical Trials DNA Disease 62